Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - Taylor & Francis
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - europepmc.org
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36–45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12–24 in a Phase III …
MH Einstein, M Baron, MJ Levin… - Human …, 2011 - scholarship.miami.edu
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36–45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
[引用][C] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Follow-up from months 12-24 in a Phase III …
MH Einstein, M Baron, MJ Levin… - Human …, 2011 - researchworks.creighton.edu
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a phase III …
MH Einstein, M Baron, MJ Levin… - Human …, 2011 - researchwithrutgers.com
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18-26, 27-
35, 36-45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36-45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
[引用][C] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine
MH Einstein, M Baron, MJ Levin, A Chatterjee, B Fox… - Human Vaccines, 2011 - cir.nii.ac.jp
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and
HPV-6/11/16/18 vaccine | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
HPV-6/11/16/18 vaccine | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III …
MH Einstein, M Baron, MJ Levin… - Human …, 2011 - pubmed.ncbi.nlm.nih.gov
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18-26, 27-
35, 36-45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36-45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
[HTML][HTML] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12–24 in a …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - ncbi.nlm.nih.gov
Results Study population. A total of 1,106 women (553 women in each group) were enrolled
and vaccinated. The number of women excluded from the Month 24 immunogenicity …
and vaccinated. The number of women excluded from the Month 24 immunogenicity …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a phase III …
MH Einstein, M Baron, MJ Levin… - Human …, 2011 - einstein.elsevierpure.com
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18-26, 27-
35, 36-45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36-45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - europepmc.org
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36–45 y), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …